regulator pain drug
food drug regulators decide recommend sale painkillers linked heart attack stroke
food drug fda advisory panel verdict hearing painkillers inhibitors sold brand names celebrex vioxx vioxx withdrawn shops merck selling fda approval fda decide benefits patients justify risks
putting vioxx shelves profits merck easier battles injured drug analysts
merck voluntarily stopped sales vioxx caused earnings slide merck shares tumbled dollars cover litigation alarm bells rung note approve heart attack stroke doubled patients drug inhibitors developed drug merck pfizer users fewer stomach painkillers
pfizer selling celebrex bextra products investigations harmful heart merck reintroduction vioxx caught analysts surprise merck kim withdrew vioxx knowing alternative therapies changed light cardiovascular observed approve vioxx unique class drugs marketed kim explained
graham fda drug safety advisory panel inhibitors calculations senate graham vioxx linked deaths stem criticism handling vioxx fda body oversee safety drugs regulators ruled patients heart disease stroke inhibitors medicines doctors cautious drugs patients factors heart disease
